Dose escalation of pramlintide improves its tolerability and efficacy
This article has no abstract so we have provided the first paragraph of the full text.
Amylin, a pancreatic hormone cosecreted with insulin, is involved in the regulation of postprandial blood glucose levels. The amylin analog pramlintide is used as a supplement to insulin treatment in patients with type 1 diabetes, because it improves control of hyperglycemia; in the initial trials, however, pramlintide also increased nausea and the risk of severe hypoglycemia. In a double-blind, randomized trial, Edelman and colleagues assessed whether the effect of pramlintide could be optimized by administering gradually increasing doses of pramlintide while simultaneously reducing doses of mealtime insulin, which was not done in previous studies.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
